Lineage Cell Therapeutics (LCTX) Net Cash Flow Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 198.34% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 467.41% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14,223.53% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 453.08% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -334.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -334.98% |
| Dec 31, 2025 | -99.07% |
| Sep 30, 2025 | 5.68% |
| Jun 30, 2025 | 57.73% |
| Mar 31, 2025 | -74.87% |
| Dec 31, 2024 | 385.80% |
| Sep 30, 2024 | 9.77% |
| Jun 30, 2024 | -174.86% |
| Mar 31, 2024 | 95.94% |
| Dec 31, 2023 | 127.93% |
| Sep 30, 2023 | 95.36% |
| Jun 30, 2023 | 359.88% |
| Mar 31, 2023 | -81.29% |
| Dec 31, 2022 | -162.25% |
| Sep 30, 2022 | -3,695.32% |
| Jun 30, 2022 | -223.65% |
| Mar 31, 2022 | -5.26% |
| Dec 31, 2021 | -6,853.33% |
| Sep 30, 2021 | -106.02% |
| Jun 30, 2021 | 94.30% |